Gilead Sciences Inc. (GILD) said it is expecting to have initial remdesivir drug data in coming weeks. The experimental drug is currently being evaluated as a potential treatment for coronavirus patients.“Multiple studies are ongoing, and we are on track to have initial data in the coming weeks,” said Gilead CEO and chairman Daniel O’Day. “If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need.”TipRanks analytics show out of 19 analysts, 10 are bullish with a Buy rating on Gilead stock, 8 are sidelined with a Hold rating …read more
Source:: Yahoo Finance
